Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction

Phase

Condition

Congestive Heart Failure

Heart Failure

Chest Pain

Treatment

Empagliflozin 10 MG

Clinical Study ID

NCT05556044

2021.717-T

Ages > 18
All Genders

Study Summary

Heart failure (HF) is one of the most important reasons for hospital admission and is associated with high mortality and morbidity. After discharge, up to 40% of patients are readmitted within 6 months and 1-year post-discharge mortality is high. The cost burden of treating patients with HF is high and ~80% of healthcare costs are related to hospital admissions.

Sodium-glucose cotransporter-2 (SGLT2) inhibitor is considered one of the four foundational therapies (ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors) for HFrEF. In particular, empagliflozin has been shown in randomized controlled trials to reduce the combined risk of cardiovascular death or HF hospitalization in HF patients with both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). However, guidelines do not specify the sequence and the timing of which therapy to be commenced. The timing of SGLT inhibitors initiation in the treatment of acute HF is not established. In particular, new-onset acute HF is a group which is understudied in the major trials to date. This study aims to evaluate the efficacy and safety of in-hospital initiation of empagliflozin in patients hospitalized for new onset acute HF, regardless of LVEF for up to 90 days of follow-up.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Subject age >18 hospitalized for primary diagnosis of acute HF
Dyspnoea (exertional or at rest) and 2 of the following signs: Congestion on chestX-ray; Rales on chest auscultation; Clinically relevant oedema (e.g. ≥1+ on a 0 to 3+scale); Elevated jugular venous pressure
Stabilization criteria (while in the hospital): systolic blood pressure ≥100mmHg andno symptoms of hypotension in the preceding 24 hours; No increase in i.v. diureticdose for 24 h prior; No i.v. vasodilators including nitrates within the last 24 hprior; No i.v. inotropic drugs for 24 h prior
NT-proBNP ≥1600 pg/mL or BNP ≥400 pg/mL. (Patients with atrial fibrillation: NT-proBNP ≥2400 pg/mL or BNP ≥600 pg/mL. Measured during index hospitalization
Heart failure hospitalization that requires the treatment of a minimum single dose of 40 mg of i.v. furosemide( or Equivalent i.v loop diuretics defined as 20 mg of torsemide or 1mg ofbumetanide)

Exclusion

Exclusion Criteria:

Cardiogenic shock
Documented history of HF with previous HF admission
Current hospitalization for acute HF primarily triggered by pulmonary embolism,cerebrovascular accident, or acute myocardial infraction
Interventions in the past 30 days prior or planned during the study: Major cardiacsurgery, or Transcatheter aortic valve implantation (TAVI), or percutaneous coronaryintervention (PCI), or MitraClip; Implantation of cardiac resynchronization therapydevice; Cardiac mechanical support implantation
Current or expected heart transplant, left ventricular assist device (LVAD),intraaortic balloon pumping (IABP), or patients with planned inotropic support in anoutpatient setting
Haemodynamically severe uncorrected primary cardiac valvular disease planned forsurgery or intervention during the course of the study
eGFR <20 mL/min/1.73m2 as measured during index hospitalization (latest measurementbefore randomization) or patients requiring dialysis
Type 1 diabetes mellitus (DM)
History of ketoacidosis, including diabetic ketoacidosis
Current or prior treatment with SGLT2 inhibitors in the 90 days prior to enrolment.

Study Design

Empagliflozin 10 MG

September 27, 2022

May 31, 2024

Connect with a study center

The Chinese University of Hong Kong
Shatin, 999077
Hong Kong
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.